Bioline RX ISIN: US09071M2052 Forum: Aktien Thema: Hauptdiskussion

https://finance.yahoo.com/news/biolinerx-reports-second-quarter-2022-110000736.html

Gestern wurde bekanntgegeben das die Zahlen und Unternehmensupdate am 16.8. kommen und da wird wahrscheinlich auf News zur Bla spekuliert.

Wie kommt der Anstieg zustande?

Das wird sich innerhalb einem Jahr sehr lohnen.🥳

Bin schon lange dabei, hoffe es geht langsam bergauf

Sehr nett die letzten Tage 👍

https://finance.yahoo.com/news/biolinerx-announces-collaboration-agreement-genfleet-110000729.html

https://finance.yahoo.com/news/biolinerx-announces-appointment-commercial-strategy-110000605.html

BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update https://www.prnewswire.com/news-releases/biolinerx-reports-year-end-2021-financial-results-and-provides-corporate-update-301503962.html - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - Announced highly positive results from additional pharmacoeconomic study indirectly comparing Motixafortide plus G-CSF versus plerixafor plus G-CSF - Cash and cash equivalents at December 31, 2021 of $57.1 million

Jepp...sieht nach langer Zeit Mal wieder ganz gut aus

360 Mio. Umsatz bei einer Marktkapitalisierung von 70 mio. Dollar 🤔 der Kurs könnte heute noch explodieren 😎

Accordingly, we believe our product has the potential to become the new standard of care for all multiple myeloma patients undergoing autologous stem cell transplantation, and potentially for other indications as well, addressing a market with estimated potential revenues of more than $360 million in the US alone.

https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-additional-positive-results-pharmacoeconomic

@AceTrunk Bin nochmal auf deutsch... Sieht nach positiven Nachrichten aus und trotzdem schießt die Aktien nicht nach oben,, 🤔??

TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ-CM: BLRX) (TASE: BLRX) a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has completed a successful pre-New Drug Application (NDA) meeting with the US Food and Drug Administration (FDA) regarding Motixafortide as a novel stem-cell mobilization agent for autologous bone marrow transplantation in multiple myeloma patients. The purpose of the meeting was to obtain agreement from the FDA on the content of the proposed NDA and, in particular, to confirm that the Company's single Phase 3 pivotal study, GENESIS, is sufficient to support an NDA submission. During the pre-NDA meeting, the FDA agreed that the proposed data package is sufficient to support an NDA submission, which the Company continues to anticipate will occur in H1 2022. "We are highly encouraged by the collaborative pre-NDA meeting that we held with the FDA, and having confirmed alignment with the agency, our NDA submission remains on track for the first half of this year," stated Philip Serlin, Chief Executive Officer of BioLineRx. "This successful meeting continues the positive momentum generated from the compelling results of our GENESIS Phase 3 study, which demonstrate a highly significant improvement over the current standard of care, alongside the positive results of the pharmacoeconomic study that we reported more recently. As a result, Motixafortide, if approved, has the potential to become the standard-of-care mobilization therapy for all multiple myeloma patients undergoing autologous stem cell transplantation, especially in light of new and more intense induction treatment regimens given to these patients, which make stem-cell mobilization more difficult than ever before," concluded Mr. Serlin. In May 2021, BioLineRx announced positive top-line results from its GENESIS Phase 3 trial of Motixafortide in stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients. The study met all primary and secondary endpoints with a very high degree of statistical significance (p<0.0001). Importantly, ~90% of patients went directly to transplantation after mobilizing the optimal number of stem cells following only one administration of Motixafortide and in only one apheresis session.